GFAP is a type III intermediate filament protein encoded by the GFAP gene, primarily maintaining astrocyte mechanical integrity and facilitating cell communication in the central nervous system (CNS) . GFAP antibodies are immunoglobulins that bind to GFAP, enabling its detection in tissues and biofluids. They are classified into:
Research-grade antibodies: Used in immunohistochemistry (IHC), Western blot, and immunofluorescence to visualize astrocytes .
Autoantibodies: Pathogenic or bystander antibodies linked to autoimmune GFAP astrocytopathy (GFAP-A), a meningoencephalomyelitis syndrome .
GFAP antibodies in cerebrospinal fluid (CSF) or serum are biomarkers for GFAP-A, characterized by:
Clinical features: Meningitis, encephalitis, myelitis, optic neuropathy, and prodromal symptoms (e.g., fever, headache) .
Association with comorbidities: Tumors (e.g., teratoma), viral infections (e.g., JC virus), and overlapping antibodies (e.g., AQP4-IgG, NMDAR-IgG) .
Alzheimer’s disease (AD): Serum GFAP levels correlate with tau pathology and astrocyte reactivity, showing 91% diagnostic accuracy in distinguishing AD from non-AD dementias .
Traumatic brain injury (TBI): GFAP release into blood indicates astrocyte damage and blood-brain barrier disruption .
GFAP antibodies are identified using:
CSF testing demonstrates higher specificity than serum due to intrathecal antibody synthesis .
Non-pathogenic marker: GFAP autoantibodies may reflect bystander inflammation rather than direct astrocyte damage .
Pathogenic role: Animal models show GFAP knockout mice develop blood-brain barrier defects and myelination abnormalities .
Immunotherapy: 70–80% of GFAP-A patients improve with steroids or IVIG, though 29% exhibit residual disability (mRS > 2) .
Relapse predictors: Persistent CSF GFAP-IgG titers correlate with recurrence risk .
Applications : Immunofluorescence (IF) Analysis
Sample type: cells
Review: Immunofluorescence for glial cell marker GFAP and pan-neuronal marker HuC/D in the ileal tissue sections derived from the indicated mice. Scale bar, 50 µm; arrows indicate the mucosal GFAP+ glial cells.